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Abstract
Background: Mandatory generic substitution (GS) was introduced in Finland at the beginning of April 2003.
However, individual patients or physicians may forbid the substitution. GS was a significant change for Finnish
medicine users. It was thought it would confuse people when the names, colors, packages, etc., changed. The
purpose of this study was to explore what medicine-related factors influence people’s choice of prescription drugs
five years after generic substitution was introduced in Finland.
Methods: A population survey was carried out during the autumn of 2008. A random sample was drawn from five
mainland counties. A questionnaire was mailed to 3000 people at least 18 years old and living in Finland. The
questionnaire consisted of both structured and open-ended questions. Factors that influenced the subjects’ choice
of medicines were asked with a structured question containing 11 propositions. Descriptive statistical analyses were
performed.
Results: In total, 1844 questionnaires were returned (response rate, 62%). The percentage of female respondents
was 55%. Price, availability, and familiarity were the three most important factors that influenced the choice of
medicines. For the people who had refused GS, the familiarity of the medicine was the most important factor. For
the subjects who had allowed GS and for those who had both refused and allowed GS, price was the most
important factor.
Conclusions: The present study shows that price, familiarity, and availability were important factors in the choice
of prescription medicines. The external characteristics of the medicines, for instance the color and shape of the
tablet/capsule or the appearance of the package, were not significant characteristics for people.
Background
Generic substitution (GS) was introduced in Finland at
the beginning of April 2003 with the aim of curbing the
rise in medical expenses for society and individuals. The
reform was preceded by heated public debate. For exam-
ple, the Finnish Medical Association and the pharma-
ceutical industry (Pharma Industry Finland) objected to
it because, for example, they were afraid of decreasing
adherence [1,2]. It was thought that generic substitution
would confuse people when the names, colors, packages
and other physical appearance of drug products chan-
ged. It is certain that generic substitution was a consid-
erable health policy reform for Finnish medicine users.
People were not used to making decisions related to
their medication. Before generic substitution, a medicine
could be changed to another product in the pharmacy
only after consultation with the physician. The reform
places the dispensing pharmacy under an obligation to
substitute a medical product, prescribed by a physician
or dentist, with the cheapest, or close to the cheapest,
interchangeable product. However, the prescriber or
individual patients may forbid the substitution.
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Previous studies have found some factors related to
patient involvement in nonprescription medicine pur-
chasing [3-6]. For example, higher educational level or
higher family income has caused the lower involvement
in nonprescription medicine purchase decisions [3].
Also a recommendation by pharmacists [5], effective-
ness, familiarity with the name or brand and safety have
influenced nonprescription medicines purchasing [4]. In
addition, people’s previous experiences of nonprescrip-
tion medicines influence their decision later [6]. How-
ever, we did not know about medicine-related factors
that influence patients’ choice of prescription drugs.
Generic medicines have caused certain problems in
many countries [7-14]. According to an Australian study
(n = 204), patients (average age 72 years) were confused
most frequently (56%) by generic and trade names,
while poor adherence was reported by 53% [15]. Also, a
new Swedish study reported that 40% of respondents
reported at least one difficulty related to generic medi-
cines and substitution. There was inconsistent informa-
tion about the effects of generic substitution (GS) on
adherence in patients who used antihypertensive drugs.
According to a Netherlands study based on prescription
data and hospital discharge records, generic substitution
of hypertensive drugs did not lead to lower adherence
compared with brand name drugs [16]. Neither was
there any difference in hospitalizations for cardiovascu-
lar diseases in the six months after the substitutions
were observed. In a Norwegian interview study, generic
substitution affected adherence because patients were
uncertain about the difference between old and new
products [14].
T h i ss t u d yw a so n ep a r to fal a r g e rs t u d ye x p l o r i n g
the risks and benefits of generic substitution in Finland.
More details on generic substitution in Finland are
described in our previous studies [17,18]. According to
our best knowledge, there are no published population
surveys dealing with factors related to medicines’ influ-
ence on people’s choice of prescription drugs. In the
present study we were especially interested in the differ-
ences between people who had refused GS and those
who had allowed GS.
The aim of this present study was to explore what fac-
tors related to medicines influence people’sc h o i c eo f
prescription drugs five years after generic substitution
was introduced in Finland.
Methods
This population survey was carried out during the
autumn of 2008. A random sample was drawn from five
mainland counties: Southern Finland, Eastern Finland,
Western Finland, Oulu, and Lapland. The sixth county,
Åland, was excluded from the sample because of its
divergent drug use culture compared with the other
counties [19]. We wanted to include in the sample indi-
viduals who had substituted their medicines, individuals
who had refused substitution, and also those who had
no experience with GS. According to the register of The
Social Insurance Institution of Finland, in 2008 only
10% of Finnish pharmacy customers refused GS.
Because the proportion was so small, we wanted to
make sure we included enough individuals who had
refused GS in the sample. Therefore, we obtained statis-
tics, by hospital district, about people who had refused
GS during 2007 from The Social Insurance Institution
of Finland. The hospital districts were located in the
counties. In 2007 altogether 778,902 individuals (exclud-
ing Åland) refused generic substitution in Finland. Of
these, 38% lived in Southern Finland, 11% in Eastern
Finland, 40% in Western Finland, 7% in Oulu, and 4.5%
in Lapland. The random sample (n = 3000) was formu-
lated on the grounds of these percentage values. So, the
sample included 1140 persons from Southern Finland,
340 persons from Eastern Finland, 1190 persons from
Western Finland, 220 persons from Oulu, and 110 per-
sons from Lapland. A flow chart of the postal survey
process is presented in Figure 1.
A questionnaire was mailed to a random sample of
3000 people at least 18 years old and living in Finland.
The sampling was conducted by the Finnish Population
Register Centre from their database. Two reminders
were sent after the first mailing round. The first page of
the questionnaire was meant for all respondents. The
second page was meant for respondents who had substi-
tuted their medicines at least once and the third page
was meant for respondents who had refused substitution
at least once. The last page was reserved for free com-
ments. The questionnaire consisted of both structured
and open-ended questions. The questionnaire was devel-
oped on the basis of our previous study of pharmacy
customers in 2003 [17], when GS was introduced in Fin-
land. The questionnaire was piloted the first time in
2003 and again in 2008 after editing. Factors that influ-
enced the subjects’ choice of medicines were asked with
a following question “Which of the following are impor-
tant when you are choosing a medication.” The question
contained 11 propositions that were price, availability,
familiarity, domestic product, excipients, shape of the
tablet/capsule, color of the tablet/capsule, appearance of
the package, manufacturer, splittability, and brand
name. The respondents could choose (circle) more than
one proposition. The propositions were almost the same
as in the earlier study. However, we added three propo-
sitions (splittability, manufacturer, brand name) that
emerged in the earlier study. Background information
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questions. Use of prescription drugs was asked with the
question “Do you use one or more prescription drugs
regularly?”
The study setting and the complete anonymity of the
respondents were in accordance with the local ethical
instructions for researchers. In Finland, questionnaire
studies are not required to be approved by the ethics
committee. The ethics committee states that respon-
dents give their approval when they answer the
questionnaire.
T h ed a t aw e r ea n a l y z e dw i t hS P S S1 7 . 0 . 1s t a t i s t i c a l
software (SPSS Inc. Chicago, IL) using frequencies and
cross-tabulations for descriptive analysis.
Results
Thirty-four questionnaires did not reach the recipients
for various reasons (e.g. addresses were wrong; the
intended recipient had moved abroad; death) or because
the recipients were excluded due to poor health or insti-
tutional care. A total of 1844 of the remaining 2966
questionnaires were returned (response rate, 62%). The
percentage of female respondents was 55%. The mean
age of the respondents was 54 years and their median
age was 55 years. The detailed characteristics of the
study population are presented in Table 1.
Price (72%), familiarity (56%), and availability (42%)
were the three most important factors that influenced
the choice of medicines (Table 2). Other characteristics
Stratified sample of 3000 people 
34 sampled 
individuals 
not 
reachable 
Final study sample of 2966 people 
1844 respondents (response rate 62%). 
40.7% (n = 751) 
no experience 
with GS  
8.6% (n = 159) 
refused GS 
 
16.3% (n = 301) 
both allowed 
and refused GS 
34.3% (n = 633) 
allowed GS 
 
Figure 1 Flow chart of the postal survey process.
Table 1 Summary of study population
Total Patients who
refused GS
Patients who
allowed GS
Patients who had refused
and allowed GS
Patients who had no
experience with GS
No. (%) No. (%) No. (%) No. (%) No. (%)
All 1844 (100) 159 (9) 633 (34) 301 (16) 751 (41)
Sex
Male 826 (45) 54 (34) 254 (40) 130 (43) 388 (52)
Female 1018 (55) 105 (66) 379 (60) 171 (57) 363 (48)
Age, yr
18-59 1118 (61) 70 (45) 404 (64) 154 (52) 490 (66)
60-94 706 (39) 87 (55) 227 (36) 145 (48) 247 (34)
Not reported 20 2 2 2 14
Mean (SD) 54 (17) 61 (18) 53 (16) 57 (19) 52 (17)
Median 55 62 53 59 52
Regularly uses prescription
drugs
Yes 1085 (59) 140 (88) 440 (70) 239 (80) 266 (36)
No 748 (41) 19 (12) 190 (30) 60 (20) 479 (64)
Not reported 11 0 3 2 6
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ability (24%), excipients (16%), manufacturer (10%),
brand name (8%), shape of the tablet/capsule (6%), color
of the tablet/capsule (1%), and appearance of the pack-
age (1%), were not as important factors to the
respondents.
For the people who had refused GS, the familiarity of
the medicine was the most important factor that
influenced their choice of medicine (Table 2). People
who used prescription medicines regularly valued that
characteristic more often than patients who did not use
prescription medicines regularly.
People who had allowed GS considered price the most
important characteristic in their choice of medicine, in
contrast to people who had refused GS (Table 2). Price
was a very important characteristic especially for
Table 2 Three most important factors that influence the choice of prescription medicines
Factors related to medicines
Price Familiarity Availability
No. No. % No. % No. %
All respondents 1551 1112 (72) 874 (56) 643 (42)
Gender Men 688 492 (72) 366 (53) 298 (43)
Women 863 620 (72) 508 (59) 345 (40)
Prescription medicines in Yes 919 633 (69) 474 (52) 403 (44)
regular use No 624 472 (76) 396 (64) 237 (38)
Age, years < 60 952 742 (78) 554 (58) 402 (42)
≥ 60 585 363 (62) 314 (54) 230 (39)
Patients who had refused GS
All 134 60 (45) 95 (71) 50 (37)
Gender Men 45 21 (47) 32 (71) 15 (33)
Women 89 39 (44) 63 (71) 35 (39)
Prescription medicines in Yes 117 52 (44) 85 (73) 44 (38)
regular use No 17 8 (47) 10 (59) 6 (35)
Age, years < 60 63 36 (57) 45 (71) 23 (37)
≥ 60 70 24 (34) 49 (70) 26 (37)
Patients who had allowed GS
All 538 448 (83) 242 (45) 203 (38)
Gender Men 212 170 (80) 87 (41) 84 (40)
Women 326 278 (85) 155 (48) 119 (37)
Prescription medicines in Yes 380 308 (81) 159 (42) 151 (40)
regular use No 155 137 (88) 82 (53) 50 (32)
Age, years < 60 340 297 (87) 159 (47) 133 (39)
≥ 60 196 150 (77) 83 (42) 69 (35)
Patients who had refused and allowed GS
All 251 178 (71) 137 (55) 119 (47)
Gender Men 108 81 (75) 46 (43) 52 (48)
Women 143 97 (68) 91 (64) 67 (47)
Prescription medicines in Yes 200 137 (69) 103 (52) 103 (52)
regular use No 49 39 (80) 32 (65) 16 (33)
Age, years < 60 124 101 (82) 76 (61) 58 (47)
≥ 60 125 76 (61) 60 (48) 60 (48)
No experience
All 628 426 (68) 400 (64) 271 (43)
Gender Men 323 220 (68) 201 (62) 147 (46)
Women 305 206 (68) 199 (65) 124 (41)
Prescription medicines in Yes 222 136 (61) 127 (57) 105 (47)
regular use No 403 288 (72) 272 (68) 165 (41)
Age, years < 60 425 308 (73) 274 (65) 188 (44)
≥ 60 194 113 (58) 122 (63) 75 (39)
Respondents could choose several options.
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medicine regularly, and for people under 60 years of
age.
People who had both refused and allowed GS also
appreciated price as the most important characteristic
(Table 2). People who did not use any prescription med-
icines regularly considered price more important than
people who used prescription medicines regularly. Also,
people under 60 years of age considered price a very
important characteristic.
For the respondents who had no experience with GS,
price and familiarity were the most important character-
istics in their choice of medicines.
Discussion
According to our study, price, familiarity, and availability
were the three most important factors that influenced
the choice of prescription medicines. People who
allowed GS or who had both refused and allowed GS
considered price the most important factor. People who
had refused GS considered familiarity much more
important than price. People who had no experience at
all with GS appreciated both of these factors. The fact
that price was the most important factor for people is in
line with our earlier study, where savings were the main
reason for accepting GS [17,18]. Finnish people also
have confidence in the effect of cheaper medicines [18].
They also held the opinion that GS does not cause any
risk to drug safety.
The people who had refused GS were a little older
than the people in the other groups. It is obvious that
especially older people appreciated the familiarity and
price of medicines. Many old people often have some-
one else buy their medicines for them. If the possibility
of GS had not been discussed before, it is probable that
t h er e p r e s e n t a t i v ew o u l dr e f u s eG S .H o w e v e r ,i ft h e
representative allows GS, it is possible that he/she can-
not take into account the familiarity of the medicine to
the old person being represented. Before GS was intro-
duced it was thought it would confuse patients when
the names, colors, packages, etc., of drug products chan-
ged [1,2]. Although people did not usually choose pre-
scription medicines on the grounds of these external
characteristics of medicines, confusions could be possi-
ble. The Finnish Medicines Agency, Fimea, publishes an
interchangeable drug list quarterly. For example, in 2008
(list July 2008-September 2008) the list included 23 sim-
vastatin products (20 mg), 39 mirtazapine products (15
mg), and 23 amlodipine products (10 mg). While phar-
macies cannot stock all these interchangeable products,
there still are many drug products to choose from.
T h er e s p o n s er a t eo f6 2 %w a sq u i t eg o o d ,s i n c et h e
present study was based on a population survey and
the sample also included individuals who did not know
what GS is. The response rate was 67% for women and
56% for men. The difference between sexes, in propor-
tion and response rate, was similar in a previous Fin-
nish population survey [20-22]. The age distribution of
the respondents was quite similar to the age distribu-
tion of the sample and background population. Young
age groups were somewhat under-represented among
the respondents. Young people usually use less medi-
cine than older age groups, and maybe for that reason
they were not motivated to answer our questionnaire.
Also, the proportion of men (45%) and women (55%)
respondents was quite well in line with the sample
(men 49%, women 51%) and the population (men 49%,
women 51%).
Conclusions
Price, familiarity, and availability were important fac-
tors in the choice of prescription medicines. The exter-
nal characteristics of medicines, for instance the color
and shape of the tablet/capsule or the appearance of
the package, were not significant characteristics for
people.
Acknowledgements and funding
None
Author details
1University of Eastern Finland, Faculty of Health Sciences, School of
Pharmacy, Social Pharmacy, P.O.Box 1627, FI-70211 Kuopio, Finland.
2University of Eastern Finland, Faculty of Health Sciences, School of
Medicine, Department of Primary Health Care, P.O.Box 1627, FI-70211
Kuopio, Finland.
3Kuopio University Hospital, Unit of Primary Health Care, P.
O.Box 1777, FI-70211 Kuopio, Finland.
Authors’ contributions
RH designed and carried out the postal survey and drafted the manuscript.
PM participated in the design of the postal survey and helped draft the
manuscript. RA participated in the design of the postal survey and helped
draft the manuscript. All the authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 20 June 2011 Accepted: 15 December 2011
Published: 15 December 2011
References
1. Finnish Medical Association: Lausunto luonnoksesta hallituksen esitykseksi
eduskunnalle lääkelain ja sairausvakuutuslain muuttamiseksi. Statement for
the Ministry of Social Affairs and Health 2002, [in Finnish].
2. Pharma Industry Finland: Lausunto luonnoksesta lakiehdotukseksi geneerisen
substituution toteuttamiseksi Suomessa. Statement for the Ministry of Social
Affairs and Health 2002, [in Finnish].
3. Gore P, Madhavan S, McClung G, Riley D: Consumer involvement in
nonprescription medicine purchase decisions. J Health Care Mark 1994,
14:16-23.
4. Hanna LA, Hughes CM: Public’s views on making decisions about over-
the-counter medication and their attitudes towards evidence of
effectiveness: A cross-sectional questionnaire study. Patient Educ Couns
2011, 83:345-351.
5. Wazaify M, Shields E, Hughes CM, McElnay JC: Societal perspectives on
over-the-counter (OTC) medicines. Fam Pract 2005, 22:170-176.
Heikkilä et al. BMC Clinical Pharmacology 2011, 11:20
http://www.biomedcentral.com/1472-6904/11/20
Page 5 of 66. The Proprietary Association of Great Britain: A Summary Profile of the OTC
Consumer London; 2005.
7. Andersen ML, Laursen K, Schaumann M, Rubak SL, Olesgaard P, Mainz J,
Lauritzen T: How do patients evaluate the newly introduced system of
substituting prescriptions? Ugeskr Laeger 2000, 162:6066-6069, [in Danish].
8. Rubak SL, Andersen ML, Mainz J, Olesgaard P, Lauritzen T: How do
practitioners evaluate the newly introduced system of substituting
prescriptions? Ugeskr Laeger 2000, 162:6070-6073, [in Danish].
9. Rubak SL, Andersen ML, Mainz J, Olesgaard P, Laursen K, Schaumann M,
Lauritzen T: How do pharmacists evaluate the newly introduced system
of substituting prescriptions? Ugeskr Laeger 2000, 162:6074-6077, [in
Danish].
10. Socialstyrelsen: Patientsäkerhet vid utbyte av läkemedel på apotek Stockholm;
2004, [in Swedish].
11. Frisk P, Rydberg T, Carlsten A, Ekedahl A: Patients’ experiences with
generic substitution: a Swedish pharmacy survey. Journal of
Pharmaceutical Health Services Research 2011, 2:9-15.
12. Gill L, Helkkula A, Cobelli N, White L: How do customers and pharmacists
experience generic substitution? International journal of pharmaceutical
and healthcare marketing 2010, 4:375-395.
13. Håkonsen H, Toverud EL: Special challenges for drug adherence following
generic substitution in Pakistani immigrants living in Norway. Eur J Clin
Pharmacol 2011, 67:193-201.
14. Toverud EL, Roise AK, Hogstad G, Wabo I: Norwegian patients on generic
antihypertensive drugs: a qualitative study of their own experiences. Eur
J Clin Pharmacol 2011, 67:33-38.
15. Sorensen L, Stokes JA, Purdie DM, Woodward M, Roberts MS: Medication
management at home: medication risk factor prevalence and inter-
relationships. J Clin Pharm Ther 2006, 31:485-491.
16. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A: Generic substitution of
antihypertensive drugs: does it affect adherence? Ann Pharmacother
2006, 40:15-20.
17. Heikkilä R, Mäntyselkä P, Hartikainen-Herranen K, Ahonen R: Customers’ and
physicians’ opinions of and experiences with generic substitution during
the first year in Finland. Health Policy 2007, 82:366-374.
18. Heikkilä R, Mäntyselkä P, Ahonen R: Do people regard cheaper medicines
effective? Population survey on public opinion of generic substitution in
Finland. Pharmacoepidemiol Drug Saf 2011, 20:185-191.
19. Lahnajärvi L, Klaukka T, Enlund H: Ahvenanmaa - itsehallittua
lääkekulutusta. Helsinki: Kansaneläkelaitos; 1997.
20. Ylinen S, Hameen-Anttila K, Sepponen K, Lindblad AK, Ahonen R: The use
of prescription medicines and self-medication among children-a
population-based study in Finland. Pharmacoepidemiol Drug Saf 2010,
19:1000-1008.
21. Turunen JH, Mäntyselkä PT, Kumpusalo EA, Ahonen RS: Frequent analgesic
use at population level: prevalence and patterns of use. Pain 2005,
115:374-381.
22. Pohjanoksa-Mäntylä M, Bell JS, Helakorpi S, Närhi U, Pelkonen A,
Airaksinen MS: Is the Internet replacing health professionals? A
population survey on sources of medicines information among people
with mental disorders. Soc Psychiatry Psychiatr Epidemiol 2011, 46:373-379.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1472-6904/11/20/prepub
doi:10.1186/1472-6904-11-20
Cite this article as: Heikkilä et al.: Price, familiarity, and availability
determine the choice of drug - a population-based survey five years
after generic substitution was introduced in Finland. BMC Clinical
Pharmacology 2011 11:20.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Heikkilä et al. BMC Clinical Pharmacology 2011, 11:20
http://www.biomedcentral.com/1472-6904/11/20
Page 6 of 6